The aim of this report is to assess the added benefit of pertuzumab in combination with trastuzumab and docetaxel compared with trastuzumab / taxane (docetaxel, paclitaxel) as appropriate comparator therapy (ACT) in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive metastatic breast cancer and compared with radiotherapy in patients with HER2-positive locally recurrent unresectable breast cancer.
http://ift.tt/2ssnHYq
Τετάρτη 14 Ιουνίου 2017
Pertuzumab -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Abstract The changes of dissolved organic matter (DOM) components during stabilization process play significant effects on its redox prope...
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου